486 filings
Page 3 of 25
144
ww3i429gac4 1i
21 Mar 24
Notice of proposed sale of securities
5:20pm
4
akkl1iuhpiu5
20 Mar 24
Crinetics Pharmaceuticals / Dana Pizzuti ownership change
6:36pm
4
y4pjlpbmc4wg 66
20 Mar 24
Crinetics Pharmaceuticals / Jeff E. Knight ownership change
6:35pm
4
nkix2n
20 Mar 24
Crinetics Pharmaceuticals / James Hassard ownership change
6:34pm
4
c6m7li4 l3
20 Mar 24
Crinetics Pharmaceuticals / Stephen F. Betz ownership change
6:33pm
4
l9hx67w18ad
20 Mar 24
Crinetics Pharmaceuticals / Marc Wilson ownership change
6:32pm
4
1c847qs8ys541rev
20 Mar 24
Crinetics Pharmaceuticals / Richard Scott Struthers ownership change
6:31pm
144
iy0y3jf qf3
20 Mar 24
Notice of proposed sale of securities
5:37pm
144
psbg1n9rbykd
20 Mar 24
Notice of proposed sale of securities
4:40pm
144
zz3f7wbg5
19 Mar 24
Notice of proposed sale of securities
4:22pm
S-3ASR
s33whgcl5ydl2i cgm
19 Mar 24
Automatic shelf registration
4:05pm
8-K
04kzjsm4osc1r7 xipf3
19 Mar 24
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
6:31am
8-K
if32tc6dq3td dv5
12 Mar 24
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
4:25pm
D
lro45w tcnngeu17ev2
11 Mar 24
$350.00 mm in equity, sold $350.00 mm, 36 investors
4:15pm
SC 13G
4npgqm
11 Mar 24
Crinetics Pharmaceuticals / EcoR1 Capital ownership change
3:34pm
4
bi5zsbg
6 Mar 24
Crinetics Pharmaceuticals / James Hassard ownership change
8:18pm
4
mgo1zljj02qq9fo5 ov
6 Mar 24
Crinetics Pharmaceuticals / Marc Wilson ownership change
8:01pm
4
s52ymte6bc
6 Mar 24
Crinetics Pharmaceuticals / Richard Scott Struthers ownership change
8:01pm
4
clsqkpw
6 Mar 24
Crinetics Pharmaceuticals / Dana Pizzuti ownership change
8:00pm
4
383v3q
6 Mar 24
Crinetics Pharmaceuticals / Jeff E. Knight ownership change
7:59pm